Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA‐1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.
Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know / Diotallevi, F; Campanati, A; Radi, G; Martina, E; Rizzetto, G; Barbadoro, P; D’Errico, Mm; Offidani, A. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - ELETTRONICO. - 35:7(2021), pp. 428-430. [10.1111/jdv.17256]
Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know
Diotallevi F;Campanati A;Martina E
;Rizzetto G;Barbadoro P;D’Errico MM;
2021-01-01
Abstract
Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA‐1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.| File | Dimensione | Formato | |
|---|---|---|---|
|
Diotallevi_Vaccination-against-SARS‐CoV‐2-psoriasis-three-things_2021.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza d'uso:
Tutti i diritti riservati
Dimensione
367.38 kB
Formato
Adobe PDF
|
367.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
